Implant Sciences Aims At Orthopedic, Brachytherapy, Stent Markets With IPO
This article was originally published in The Gray Sheet
Executive Summary
Implant Sciences Corp., currently developing a method for embedding radioactivity into coronary stents in partnership with Guidant, is looking to raise $6-7 mil. in an initial public offering this spring, according to a prospectus filed Feb. 10 with the Securities and Exchange Commission.